Clinical and hematologic features of patients with AIHA at enrollment
| . | All (N = 47) . | wAIHA (N = 22) . | CAD (N = 19) . | Mixed/atypical (N = 6) . |
|---|---|---|---|---|
| Distribution % | 100% | 47% | 40% | 13% |
| Median age, y (range) | 69 (19-94) | 71 (19-89) | 66 (33-94) | 80 (25-89) |
| Males/females, N | 25/22 | 12/10 | 9/10 | 4/2 |
| Hematologic parameters | ||||
| Hb (g/dL) | 7.6 (3.2-10) | 7.4 (5-10) | 7.6 (5.8-10) | 8.2 (3.2-9.7) |
| Hb < 8 g/dL, n (%) | 27 (57%) | 13 (59%) | 11 (58%) | 3 (50%) |
| Ht (%) | 22.7 (8.4-33) | 23 (13.8-33) | 23 (17-30) | 21 (8.4-28.4) |
| LDH (U/L) | 374 (153-2083) | 422 (195-2083) | 341 (153-1073) | 293 (228-430) |
| Ret (×109/L) | 121 (10-266) | 106 (42-266) | 130 (44-191) | 136 (10-204) |
| BMRI | 76 (2.7-120) | 83 (2.7-117) | 73 (26.8-119.8) | 77 (17.5-120) |
| EPO (U/L) | 56 (10-457) | 51 (10.8-230) | 62 (17-457) | 91 (10-327) |
| BM features | ||||
| Cellularity, % | 48 (10-95) | 45 (10-80) | 43 (18-80) | 75 (40-95) |
| Hypercellularity, n (%) | 26 (60) | 10 (56) | 11 (58) | 5 (83) |
| Dyserythropoiesis, n (%) | 34 (79) | 14 (78) | 15 (79%) | 5 (83) |
| Fibrosis, n (%) | 17 (41) | 7 (39) | 8 (47) | 2 (33) |
| Lymphoid infiltrate, n (%) | 37 (90) | 14 (88) | 17 (89) | 6 (100) |
| Lymphoid infiltrate, % | 5% (1-13) | 7.5% (2.5-13) | 7% (2.5-12) | 5% (1-5) |
| . | All (N = 47) . | wAIHA (N = 22) . | CAD (N = 19) . | Mixed/atypical (N = 6) . |
|---|---|---|---|---|
| Distribution % | 100% | 47% | 40% | 13% |
| Median age, y (range) | 69 (19-94) | 71 (19-89) | 66 (33-94) | 80 (25-89) |
| Males/females, N | 25/22 | 12/10 | 9/10 | 4/2 |
| Hematologic parameters | ||||
| Hb (g/dL) | 7.6 (3.2-10) | 7.4 (5-10) | 7.6 (5.8-10) | 8.2 (3.2-9.7) |
| Hb < 8 g/dL, n (%) | 27 (57%) | 13 (59%) | 11 (58%) | 3 (50%) |
| Ht (%) | 22.7 (8.4-33) | 23 (13.8-33) | 23 (17-30) | 21 (8.4-28.4) |
| LDH (U/L) | 374 (153-2083) | 422 (195-2083) | 341 (153-1073) | 293 (228-430) |
| Ret (×109/L) | 121 (10-266) | 106 (42-266) | 130 (44-191) | 136 (10-204) |
| BMRI | 76 (2.7-120) | 83 (2.7-117) | 73 (26.8-119.8) | 77 (17.5-120) |
| EPO (U/L) | 56 (10-457) | 51 (10.8-230) | 62 (17-457) | 91 (10-327) |
| BM features | ||||
| Cellularity, % | 48 (10-95) | 45 (10-80) | 43 (18-80) | 75 (40-95) |
| Hypercellularity, n (%) | 26 (60) | 10 (56) | 11 (58) | 5 (83) |
| Dyserythropoiesis, n (%) | 34 (79) | 14 (78) | 15 (79%) | 5 (83) |
| Fibrosis, n (%) | 17 (41) | 7 (39) | 8 (47) | 2 (33) |
| Lymphoid infiltrate, n (%) | 37 (90) | 14 (88) | 17 (89) | 6 (100) |
| Lymphoid infiltrate, % | 5% (1-13) | 7.5% (2.5-13) | 7% (2.5-12) | 5% (1-5) |
Atypical AIHA were 2 DAT-negative patients. Values are given as median (range) unless otherwise specified.
Ht, hematocrit; Ret, reticulocytes; BMRI, bone marrow responsiveness index; BM, bone marrow; EPO, endogenous erythropoietin.